Comparative Pharmacology
Head-to-head clinical analysis: LATUDA versus SYLEVIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LATUDA versus SYLEVIA.
LATUDA vs SYLEVIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Lurasidone is an atypical antipsychotic with high affinity for dopamine D2, serotonin 5-HT2A, and serotonin 5-HT7 receptors, and moderate affinity for serotonin 5-HT1A receptors. It acts as an antagonist at D2 and 5-HT2A receptors, and as a partial agonist at 5-HT1A receptors. The exact mechanism of action in schizophrenia and bipolar depression is unknown but is thought to involve modulation of these receptors.
Dexmedetomidine is a selective alpha-2 adrenergic receptor agonist, producing sedation, analgesia, and anxiolysis by reducing norepinephrine release in the locus coeruleus.
40 mg orally once daily initially, titrated to 80-160 mg once daily; maximum 160 mg/day. Administer with food (at least 350 calories).
Adults: 400 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 20–40 hours (mean about 29 hours) in adults, supporting once-daily dosing. Steady-state is reached within 7 days.
Terminal elimination half-life is 27-33 hours in adults with normal renal function. Clinical context: Requires dose adjustment in renal impairment (creatinine clearance <30 mL/min reduces clearance by 50%).
Approximately 80% of the dose is eliminated in feces (mostly as unchanged drug and metabolites) and about 10% in urine. Less than 2% is excreted as unchanged lurasidone in urine.
Renal excretion accounts for approximately 70% of the administered dose as unchanged drug, with biliary/fecal elimination contributing 20-30% (primarily as metabolites).
Category C
Category C
Atypical Antipsychotic
Atypical Antipsychotic